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ABSTRACT 
 
Antiretroviral therapy (ART) offers a powerful intervention in HIV but 
effectiveness can be compromised by inadequate adherence. This paper is a 
detailed examination of the experience of medication in a purposively selected 
group of people living with HIV. In-depth interviews were conducted with 10 
HIV positive, West African women of black heritage living in London, UK. This 
group was of interest since it is the second largest group affected by HIV in the 
UK. Interviews were subjected to interpretative phenomenological analysis 
(IPA), an idiographic, experiential, qualitative approach. The paper details the 
women’s negative experience of treatment. ART can be considered difficult and 
unrelenting and may be disconnected from the women’s sense of health or 
illness. Participants’ social context often exacerbated the difficulties. Some 
reported an improvement in their feelings about the medication over time. 
These findings point to some intrinsic and social motivators which could act as 
spurs to adherence. 
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INTRODUCTION 
 
Morbidity and mortality associated with HIV infection can be dramatically 
reduced by effective ART (1) as can the risk of onward transmission to 
uninfected sexual partners (2). However, full benefit of treatment relies on both 
prompt uptake of a clinically indicated offer and high levels of adherence (90-
95% of doses taken) in the long term (3). These behaviours are necessary not 
only for efficacy but also to prevent viral resistance and the exhaustion of 
treatment options (4). Despite this, existing research suggests that adherence to 
treatment may frequently fall short of the necessary threshold, with some 
studies reporting only 50-70% of doses taken (5, 6).  
 
HIV is highly prevalent in Sub-Saharan Africa, and diaspora communities from 
Sub-Saharan Africa in the UK have disproportionately high rates of HIV infection 
(7). Following men who have sex with men (MSM), men and women of black 
African heritage make up the largest group affected by HIV in the UK (7). It is 
therefore worthwhile exploring the experiences and behaviours of people from 
Sub-Saharan Africa living with HIV both in their home countries and abroad in 
order to more fully understand their experiences both in terms of living with 
HIV and adhering to ART.  
 
Several authors have examined the experiences of those living with HIV in Sub-
Saharan Africa, both in terms of barriers and facilitators to taking treatment. One 
such paper discussed the notion that adherence to ART is in fact higher in Africa 
than in resource rich settings (8). These authors argued that this was the case 
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because people starting ART were sicker at treatment initiation and experienced 
tangible benefits over time. In contrast, people with HIV in the UK are 
encouraged to start treatment before symptoms emerge (9) and many do not 
experience discernible benefits from starting ART. For those living in Africa, the 
need to meet family responsibilities was found to be a major motivator to 
remain adherent to their treatment. Conversely, Adewuya et al. (10) looked at 
adherence for those living with HIV in Nigeria and found psychopathology and 
low levels of social support were significant correlates of low levels of adherence.   
 
There are a number of papers exploring the lives of people of black African 
heritage living with HIV in countries outside Africa. Doyal and Anderson (11) 
used qualitative methods to look at the experiences of African women living in 
London with HIV, and found that issues around gender and migrant status were 
as important as their HIV status. Living in the UK granted women access to 
treatments they would not have had in Africa but, consistent with other work 
(12), this came at the price of living far away from home. The same authors also 
explored the lives of heterosexual African men living with HIV in London (13) 
and reported that men found it hard to accept their HIV status, which was 
considered an assault on manliness. Men were also likely to be isolated, living 
away from friends and family.  For many people of black African heritage living 
with HIV in London, issues such as housing, lack of money and concerns about 
immigration status, confidentiality, stigma and difficulties accessing healthcare 
may be more pressing than considering and dealing with their seropositive 
status (12, 14).  
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Several authors have focused on the impact of HIV-related stigma for people of 
black African heritage living with HIV outside Africa (12, 15). One strong 
qualitative paper spoke to key figures within healthcare about African people 
living with HIV in the UK (14) and found that despite the availability of effective 
ART since 1996, African patients, especially men, still tended to access care late 
and that patients reported pathways to care as being overly complex. African 
participants living with HIV in the Netherlands (15) felt stigmatised through 
social and physical distance, words, and silence. This had various consequences, 
including a deleterious effect on adherence. For some, keeping their HIV status 
secret was more important than adhering to medication. Flowers et al. (12) 
found that stigma could lead to additional problems for people of black African 
heritage living with HIV in London, including lack of social support and isolation. 
Accessing support services runs the risk of revealing one’s HIV status. In a close-
knit community where HIV is highly stigmatised, as is the case for many African 
communities, this may not be a risk worth taking, potentially impacting 
negatively on adherence (12).  
 
There is less work looking specifically at the challenges that people of black 
African heritage living with HIV face in adhering to their medication. One review 
(16) looked at 24 qualitative papers on adherence in HIV, and although some of 
these authors concentrated on particular sub-groups of participants, only Sankar 
et al. (17) focused on participants of African origin. These authors used 
discourse analysis to examine the influences informing the behaviour of the 
participants and found that although the physician’s voice commonly served to 
facilitate adherence, influential social voices - such as those who suggested the 
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medicines do not work or are toxic - acted as barriers to adherence. This paper 
is concerned with external discourses informing the behaviour of the 
participants and could be usefully complemented by work focused on the 
personal, lived experience of the participants. 
 
A wealth of interventions aiming to improve adherence to ART have been 
undertaken. A recent review (18) has found some encouraging results with 
multi-component interventions to improve adherence to ART. However, effects 
are often small and short lived. There also appears to be a dearth of 
interventions focusing specifically on people of black African heritage living with 
HIV and the particular challenges they may face with adherence.  
 
In order to develop effective interventions to promote adherence, we need to 
address the right barriers and fully utilise facilitators. This constitutes a complex 
area worthy of more detailed examination, especially in a population who is 
under-researched but over-represented within HIV care. There is a strong case 
to suggest that experiential qualitative approach is warranted to increase 
understanding of patients’ beliefs about treatment for HIV (18).  
 
Previous research (5) has suggested that patient beliefs about the necessity of 
being on ART impact both uptake and adherence to ART. It is logical to suggest 
that personal beliefs, circumstances and emotions will impact upon each 
person’s ability to adhere in different ways. For these reasons, we have 
employed Interpretative Phenomenological Analysis (IPA) (19) to provide an in-
depth exploration of the experience of treatment in a group of women of West 
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African heritage living with HIV in London with documented difficulties with 
adherence to ART. Indeed, Skinta and colleagues (20) have demonstrated that 
IPA can be used extremely effectively to uncover the nuances and details within 
the lifeworlds of a small group of people living with HIV, as we aim to do in this 
paper. IPA is an idiographic, experiential, psychological methodology which 
provides a detailed analysis of convergences and divergences in individuals’ 
accounts of their lived experience.  
 
IPA was selected over other qualitative methods since it is particularly well 
suited to health psychology research (21), and is an experiential method (19); as 
we have seen, there is a need for more experiential work to help unpack 
complex individual experiences of barriers and facilitators to ART. Given the 
potential for nuanced and multi-layered findings within the topic, we believe 
that IPA was a stronger choice than other experiential qualitative methods such 
as grounded theory (22, 23), narrative analysis (24) or descriptive 
phenomenology (25).  IPA is well suited to subjects that are multifaceted and 
equivocal; it allows the researcher to focus in on a particular phenomenon, 
rather than a whole life story, and it allows space for idiographic variation, 
rather than searching for essential structures or basic theory. A detailed 
description and interpretation deriving from an IPA reading of these women’s 
experiences will enable the reader to explore the lifeworlds of these women and 
understand the barriers they face in adhering to ART, together with factors that 
have helped improve adherence. Although exploratory, these types of findings 
can, as part of a broader repertoire of approaches, act to inform the 
development of interventions, for example by helping to calibrate quantitative 
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instruments and by offering content material to constructs in interventions 
which involve vignettes and narratives. 
 
 
METHOD 
 
All authors contributed equally to the design of the study. 
 
Sampling 
Participants for this study were part of a larger cohort selected for a thematic 
analysis. This group was recruited from the specialist NHS HIV outpatient clinics 
at two London hospitals. Criteria for selection to this larger sample were that 
patients must be of Black African or Caribbean heritage, living in the UK, English 
or French speakers, and to be currently being treated with ART for HIV. Further 
to this, participants were deemed, following study of blood results and notes, as 
well as consultations with healthcare professionals, to have some evidence of 
adherence difficulties with their medication.  The first and third author worked 
closely with clinicians at the participating hospitals to look for spikes in viral 
load within potential participants’ blood results, as well as reviewing potential 
participant notes to look for discussions about adherence difficulties. Further to 
this, clinicians suggested potential participants who they believed to be 
struggling with adherence.  
 
For this paper, we conducted a more detailed examination of how personal 
factors come into play within a more closely designated group. From the larger 
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cohort, we selected 10 West African, English speaking women for this study. The 
principles of IPA require working with small, homogeneous samples (19). 
Smaller samples allow for greater idiographic detail to be uncovered. Whilst the 
larger, thematic study gives a wider illustration of the topic, we have narrowed 
down on one key group. Our small sample enables us to explore the experiences 
of this group in great detail.  
 
It may be argued that a smaller sample results in a loss of generalizability. 
However, it is not suggested that one can make specific generalisations from IPA 
studies in the same way that one can from traditional, quantitative psychology 
studies. Instead, the interpretation of accounts in a study will present a 
particular perspective as accurately and with as much resonance as possible. 
Sandelowski argues that: “the real business of case studies is particularisation, 
not generalisation” (26, p. 527). Hence, in-depth case study work of this nature 
can complement broader, traditional quantitative work by adding texture and 
resonance to the existing picture but also by problematizing some assumptions 
in quantitative work and leading researchers to expand their construct base. 
 
Of course, there may be important information about facilitators to adherence to 
be gleaned from people living with HIV who are adherent to their medication. 
However, there is existing, high quality qualitative literature which compares 
excellent and sub-optimal adherers to ART (28). In this instance, we were 
interested in providing a new dimension to the picture by looking in-depth at 
the idiographic experiences of non-adherers. In addition to this, since IPA works 
with a principle of homogeneity to order to ensure that the phenomenon in 
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question is foregrounded (19), a decision was made to explore the experiences 
just of those who appeared to have difficulties with adherence. This decision to 
focus on a sample of West African women was also guided by IPA’s principle of 
homogeneity and a desire to respect demographic differences of gender and 
heritage. Future researchers may wish to focus on the experiences of men. 
Details of participants can be found in Table i.  
 
Place table i about here  
 
Approval for this study was granted by the City and East London Research Ethics 
Committee. Informed consent was taken in a session prior to interview, in which 
the procedure was explained to participants and any questions about taking part 
were answered.  
 
 
Interviews 
An interview schedule comprised of open questions addressing views on 
treatment was drawn up. Interviews took place in consulting rooms at the two 
hospitals and were audio recorded before being transcribed verbatim. The 
interviews were conducted by the first and third authors. The interviewers 
emphasised that the participants were the experts on the topic of ART, and used 
open ended questions to encourage participants to speak candidly about their 
experiences. Any interesting or unexpected leads established by the participants 
were followed up by the interviewers. The interviews themselves lasted 
between 23 and 70 minutes (mean = 47 minutes). 
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Analysis 
The analytic process followed the guidelines for IPA (19). Interviews were 
transcribed by a professional transcribing service, and then checked for 
accuracy by the first author. Each transcript was first analysed in its own terms. 
The transcript was read a number of times. Notes of descriptive, linguistic and 
conceptual features were recorded in one margin. These notes were then 
transformed into themes capturing the experience in a nuanced, detailed and yet 
succinct manner. Themes were clustered into groups, bearing in mind 
intrapersonal patterns of convergence and divergence, and given super-ordinate 
theme titles. Once this was complete for each transcript, further interpersonal 
patterns of divergence and convergence were then traced across the sample, 
which resulted in a master table of themes for the group.  
 
The first two authors took the lead on analysis. Initial analytic work by the first 
author on the first three transcripts was checked by the second author who, by 
independently reading the transcripts, refined, modified and deepened the 
thematic schema. Once the two authors reached consensus on the early 
transcripts and moved on to subsequent interviews the second author’s role 
shifted more to auditor, checking claims were warranted from data presented. 
 
The master table of themes for the group provided the springboard for the first 
draft write up, but analysis was continually refined and honed during the 
writing process. Thus, analysis of the participants’ experiences continued during 
the writing up of the study, as certain themes and quotations revealed 
themselves to be more potent  in uncovering the stories of the participants (19). 
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All authors contributed to the final write up of the findings. IPA involves  a 
double hermeneutic in order to make sense of the participant’s sense making 
around their own experience (19). Thus the themes in the results section are 
evidenced by extracts taken from participant’s transcripts followed by 
interpretations of those extracts from the authors. Those interpretations stay 
close to the respondent’s words and offer a combination of empathic and 
reflective reading. This also provides a further layer of validity as the reader of 
the paper is themselves enabled to check the viability of the unfolding account in 
the light of the evidential base and the interpretative narrative. 
 
 
RESULTS 
 
Analysis revealed three master themes, which tell the story of difficult 
adherence and how it may improve over time. In the first theme, we can see that 
all of the women struggled with different aspects of the medication, making 
adherence challenging. In the second, it is shown that experience of medication 
can improve as time goes on. Finally the third theme explores spurs to 
adherence. This table of themes is reported in Table ii:  
 
Place table ii about here  
 
 
 
The negative experience of medication 
 13 
 
Nine of the 10 of the participants talked about the experience of taking the 
medication as being a negative force in their lives. These experiences broke 
down into four sub-themes, which were: An aversive regime; Disconnect 
between treatment and feeling of health; Feeling trapped in a monotonous life 
sentence; and Social context exacerbates the difficulties.  
 
An aversive regimen 
 
Most of the women found their medication regimen extremely onerous. A 
number commented on the sheer difficulty of having to take so much 
medication: 
 
Before in the night I used to take 20-something tablets and then in 
the morning, around 8, and it was too much, too much. (P7) 
 
P7 is overwhelmed by the large a number of tablets, a sentiment echoed by P1:  
 
When they bought the medication to give me loads in a cup maybe 13, 
15, I say I don’t want to drink this medicine, it’s too much. 
 
Many of the participants noted features of the appearance of the tablets which 
distressed them. P3 comments on their colour:  
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They are orange and blue, they’re not the regular colour you would 
expect so for me, I am seeing something that just looks unreal really.  
 
For P3, the colours of the tablets are a signal that something out of the ordinary 
is going on. The tablets are impossible to ignore. It may be that P3 is thinking 
that the loud colour, almost a warning siren to the outside world that 
stigmatised ill health is happening here. P9 seems to feel suspicious of the 
tablets due to their unusual appearance:  
 
Everything, the size, the colour. If it was just this innocent, white 
tablet common size that you get with paracetamol.  
 
P9 unfurls a moral taxonomy. Paracetamol are small and white and therefore 
innocuous. By contrast the ART tablets seem to be imposing and sinister. While 
this most directly implicates a quality of the treatment, it may also point to a 
perception of a judgement on the condition. The tablets for HIV are big and 
bright and an obvious sign to the patient and to others of what is frequently  
considered a shameful illness. 
 
A number of women talk about the uncomfortably large size of the tablets:  
 
When you have three tablets to take at the same time you are scared 
and especially when it is big, you are very scared because when you 
take it sometimes you feel it on your chest and it is like you’re going 
to throw up. (P4) 
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We can see here how pervasive the dread of the tablets is. While the fear is a 
physical one, it also feels emotional. Perhaps the bigger the tablets are, the 
bigger the problem they seem to represent; three big tablets signify one very 
large enemy.  Similarly for P3: 
 
The tablets are big, they are ugly and they’re not easy to take.  
 
Again the word ugly suggests an emotional as well as a physical reaction to these 
tablets. After all, who would expect a tablet to be beautiful? For P3, ART has 
become personalized.  
 
Frequently, the aversive features of the tablets lead to physical difficulties in 
taking them. Participants have had to find strategies to help them overcome this:  
 
If I take my tablet I have to put something in my mouth immediately 
to take away the taste in my mouth, otherwise I will be feeling sick 
like I want to throw up. (P4)  
 
The physical act of taking the tablets is invasive, disturbing and disgusting. The 
act of swallowing ART is physically repellent to P4, while P2 describes ritualistic 
behaviour to deal with the repellence of swallowing the tablets:  
 
Just be going around looking at, go in, go eat again and come back, 
make sure that there is good there and I don’t like taking one I just it 
take it all once and I will have my drink. 
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The procedure is elaborate and involved, ensuring the body is forearmed with 
good food to withstand the invasion of the noxious substance. The preparations 
need to be carried out carefully but the ingestion of the tablets is then done as 
quickly as possible. 
 
So great is the aversive conception of ART that, for P3, the very anticipation of 
the pills makes her feel sick:  
 
Sometimes it’s just overcoming the thought of taking them before you 
can take them and get rid of them.  
 
The anticipation of disgust becomes disgust in itself. The thought of the tablets 
seems to create more of an issue for P3 than the tablets themselves. The term 
‘get rid of them’ is interesting; the tablets are taking on the mantle of an aversive 
entity, perhaps in part becoming a symbol of the condition they are intended to 
alleviate.  
 
Participant 9 powerfully summarizes the problem: 
 
I felt that the medication put me off. The number, the size, the smell, 
different things and at times I just don’t want to think about it. 
 
P9 reminds us the different aversive features of the tablets can all come together 
producing an obnoxious gestalt. And P9 also here explicitly links this to the 
important consequence; the regimen is so unpleasant that patients try to avoid 
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having to think about it. It is not surprising then that non-adherence happens, 
either as a deliberate avoidance or as result of forgetting something so 
unpleasant. 
 
Disconnect between treatment and feeling of health 
 
A number of participants pointed to a problematic gap between the treatment 
they were undergoing and their personal sense of being well or ill:  
 
It’s just taking the tablets I hate, because sometimes there is an 
improvement and sometimes there is not. (P2) 
 
P2 feels a disconnect between the unrelenting routine of the medication and the 
erratic outcome of her blood results. P2 believes she is taking the tablets 
correctly, and yet the results do not reflect this. One can see how this experience 
of the medication would contribute to a sense of confusion and lack of faith in 
ART.  Meanwhile, for P3:  
 
I was taking them regularly and then suddenly they stopped working 
for some reason. 
 
P3 had to switch to a new combination when a previous one failed. We can feel 
confusion and sense of injustice from P3, as she believed she was doing all she 
could with a combination she was quite happy on; and yet the blood results then 
gave a different story. This hits her hard: 
 18 
I really felt it because I knew I was taking them regular and it was 
only two tablets a day and then to find out I had that resistance and I 
had to find another cocktail, that was really sad. 
 
P4 also experienced some difficulties with medicines not controlling the virus. 
However for her, the emphasis appears to be more on a lack of any sense of 
agency or control:  
 
My doctor then change it and then I had another medication after 
some time the medication failed and I was asked to change 
medication again. 
 
P4 presents herself as entirely passive in this extract; these are all things that 
happened to her, rather than things in which she took an active part. Her doctors 
make the decision; her medication is the thing that fails; she does as she is asked. 
One can see how together, these experiences result in a feeling that since the 
medications do not work (for her), there may be less reason to be engaged and 
less opportunity to feel in control of the situation.     
 
 Feeling trapped in a monotonous life sentence  
 
A number of the women experienced being on ART as monotonous and 
relentless:  
 
 19 
They will tell you that you have to take it. It’s the words ‘for life’ I 
hate, I can’t stand it. (P2)  
 
‘For life’ has echoes of the most severe prison sentence. Of course the tablets are 
also for life, in the sense of, to preserve life, which serves to remind her of the 
seriousness of her predicament. P2 also feels the routine is something that has 
been imposed upon her by an external force, ‘they,’ who force her to ‘take it’ in 
the way one may be forced to submit to an unavoidably heavy life burden.  
 
P10 says:  
 
It’s just like, me, another me going around the house, really, at least 
you control your partner in some way, but this thing you have to be 
carrying everywhere. 
 
P10’s medication is a burden from which she can never escape. She 
anthropomorphises it in a striking fashion, seeing the medication as ‘another me.’ 
However, it is the medications that have the upper hand, wresting essential 
control away from P10.  
 
P5 vividly describes the sense of exhaustion and ennui that arise from being 
trapped by this life sentence of medication: 
 
You know the side effect of it, you still can’t be bothered because you 
have to do it every day, you get tired. It’s not like two times a week. 
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The unrelenting toll means that she cannot always bring herself to take them 
correctly. As a result of this sense of being trapped and the consequent 
exhaustion and depression, P5 explicitly invokes a desire for a break from the 
medication: 
 
Let me take a break because after all I am still going to be on it for 
the rest of my life.   
 
P4 echoes the fantasy of a positive break from the turgid routine:  
 
Sometimes I just want to treat myself, I don’t want to take this 
medication today.   
 
This extract suggests that a day away from medication is a treat to be savoured.  
 
Several of the women suggested that not adhering to their tablets was a way to 
try to escape the feeling that the regime is a repressive life sentence. P9 a seems 
to hint at deliberately ‘forgetting’ her tablets in order to escape the monotony, 
saying:  
Makes me think, it gets too much in my face… so at times I forget.   
 
P3 points to how the nature of non-adherence can itself become habitual:  
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One week became two, two weeks became three and so forth and it 
was just easier not to take anything.   
 
This extract accurately captures a growing sense of inertia as time slips away, 
making it easier to be in denial about the need to take the tablets P5 vividly 
captures the process:  
 
Let me get my freedom not taking it. So I put it in one corner and I 
carried on living my daily life without taking my tablets.  
 
Hiding the tablets away in a ‘corner’ gives her an occasional liberation from the 
unrelenting regimen. 
 
Social context exacerbates the difficulties   
 
For P6, the weekends can be a barrier to adherence:  
 
The time I usually forget is weekends. Like maybe 30 minutes after, I 
say, ‘Oh my medication!’ Then just sneak in and take my medication, 
that’s it.  
 
P6 is married with six children, so it could be that the demands of family life at 
the weekend make it harder for her to keep to her medication routine.  
 
Relatedly, P9 says:  
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Initially people were living with me so because of the crowd I couldn’t 
take it.   
 
The crowd suggests a distancing from the people who share her house, giving a 
sense of how isolated P9 feels in her condition. She still feels unable to be open 
about her medication and therefore take it properly.  
 
The inhibition extends to the work environment: 
 
I don’t want to be popping pills everywhere and if you’re popping pills 
at work all the time people look at you, are you alright? (P9)  
 
P9 sees the tablets as something that should be hidden rather than something 
that can be openly taken and explained in front of colleagues.  This is echoed by 
P2 who says: 
 
 In a way you look like a drug addict.  
 
This emphases the sense of shame she perceives in relation to her condition and 
the treatment for it. 
 
P5 talks about how difficult it can be to remain adherent in the face of family 
circumstances, in this case, her husband dying of cancer:  
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I have to run around my girls now, my husband is diagnosed bowel 
cancer lying in the hospital, can’t stand this. And still you want me to 
carry on remember about taking the pills?   
 
These family pressures make the struggle to remain adherent in the face of the 
already challenging sense of a life sentence that much harder.  
 
The reverse social context may also be a problem. P8 reports the impact of 
losing her partner: 
 
He left me last year, I was really pissed off, I was really down. I 
stopped taking my medication completely, the virus was up and down.  
 
We can see here how the breakdown of a relationship can become a barrier to 
adherence. 
 
 Temporal improvement in the experience of medication 
 
Four of the women do express that there has been an improvement in the 
experience of taking the tablets, demonstrating how adherence can be a 
temporally dynamic process. P10 talks about how, over time, her attitude 
towards the tablets has normalised, so that they no longer feel threatening: 
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But the way I see it right now, it just like any normal (laughs) 
medication. Sense of the speaking, they just like paracetamol to me, 
so it’s become natural for me to have them anywhere I go, yeah.  
 
Use of the word ‘normal’ here suggests that previously, P10 had seen HIV 
medications as being ‘other.’ However, as time has gone on, the medications 
have become much more every-day, ‘natural’ things to keep in close proximity to 
her at all times.  
 
P9 says:  
 
Treatment’s working, I’m using it. It’s working for me so I’ve been 
able to overcome some of my [...] 4I take it and I guess my body seems 
to be tolerating it fine, so it’s better than before definitely.  
 
P9 seems to be outlining a very pragmatic relationship with her medication. She 
is using it, and it is working and this is an improvement over time. Similarly for 
P1 an improvement in her condition seems to lead to a more positive attitude 
towards the medication:  
 
Before I used to put it a lot in my mind – I’m HIV positive, oh God, how 
can I be – but now I am ok. Don’t worry about your sickness, it’s 
undetectable, don’t worry, you are fine, you are fine, just be taking 
your medication. Since that time, the fear has gone.  
                                                        
4 [...] indicates editorial elision 
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The effectiveness of the medication has had a direct impact on P1’s feelings of 
fear, helping her to accept her condition and feel less concerned about it.  
 
P4 reported a positive experience with the tablets she is currently taking:  
 
So far, so good, the one I’m taking now is fine, because they are not 
too big and I have time to take them at home.  
 
We can see here P4’s emphasis on the practical aspects of ART. If the tablets are 
easy to swallow and do not interfere with her day too much, P4 feels satisfied 
with taking them.  
 
Spurs to adherence  
 
Amidst the negative portrayal of the experience of ART medication, six of the 10 
women discussed several facilitators which helped them keep to the treatment 
regime. This theme broke down into three sub-themes: Intrinsic motivators; 
Relational motivators; and Sense of collaborative agency over the medication.  
 
Intrinsic motivators 
 
Both P2 and P8 recounted how memories of previous ill health worked as a 
motivator in terms of adherence. P2, who had previously been hospitalised, says:  
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In my case why I remember is like if I stop taking it I am always in the 
hospital. I am always, I will just go down.  
 
P2 now recognises that not adhering to her medication has serious 
consequences for her. Her phrase ‘just go down’ gives a sense of the rapid 
decline that can ensue if she is not vigilant. Similarly, P8 says:  
 
Two years ago I stopped taking my medication. I was tired, I was 
pissed off so I just leave it and I travel for a week. But when I came 
back I collapsed. I was in hospital for two months, but from that I 
have been taking my medication on time. If I am going somewhere I 
will take it with me.  
 
Again, we can see how serious consequences of previous non-adherence lead to 
improved adherence in the present.  
 
P1 talks in a similar but more generic way:  
 
Before the starting it was difficult but when I start taking it I feel 
better, I say I’m not going to joke with this because I need my life so I 
take it.  
 
P1 is expressing her realization that when she doesn’t take the tablets she feels 
unwell and this spurs her on to adherence. 
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P10 describes how gaining knowledge about her condition worked as an aid for 
her adherence:  
 
I went to college to have, um, an advanced diploma in HIV and STD 
studies. So after I get more knowledge about it I decided to come back 
to my medication.  
 
This extract demonstrates the practical value of gaining knowledge. As she 
learnt about the condition and how the medications work, P10 made her own 
choice to take ART again.  
 
P8 has her own motivational spur: 
 
You know it’s gonna, only go away if you are taking your medication. 
You become like a normal person.  
 
P8 is attempting to gain some value from the pejorative stigmatized image of 
HIV.  The desire to rid the shame and become ‘normal’ again becomes 
motivation for adhering to medication.  
 
Relational motivators 
 
Some of the women reported family to be an important motivator for adherence:  
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I have to take this thing to be here for my family, even when I was 
married I have to be there for my husband and my children. That is 
something you have to be looking at, if not then what are you living 
for? (P2) 
 
My doctor said to me no… it’s only, you are going to be on tablets for 
the rest of your life (big sigh). I found it very, very difficult to accept it, 
but initially I said I have to because of the sake of the baby. (P5) 
 
P5’s love for her unborn baby worked as a powerful motivator to help her accept 
both her condition and its treatment and to try to adhere.  
 
Members of the family can also encourage adherence: 
 
Sometimes she [friend] and my daughter are so fussy now, every 
minute they call me to make sure you are take it. (P2)  
 
P6 appreciates the positive feedback she receives from her family in response to 
an improvement in her appearance as a result of taking the medication: 
 
So I do take them then gradually, gradually, everybody was smiling at 
me again, even my smallest, ‘Ah mummy, you are back. You are not 
like a skeleton again’. 
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P6’s daughter’s use of the word skeleton here is interesting, because without 
ART, P6 is depicted as someone who is close to death. The medications bring her 
back from this fate, something that is reflected back to her via her relationship 
with her daughter.  
 
P1 also asserts the value of people seeing her looking better if she takes the 
medication. When she adheres to her medication, she looks healthy, something 
that is reflected back to her via her relationships with others. In this way, this 
feedback from her relationships works as a motivator to adhere: 
 
If you don’t take your medication people will know that you are sick 
but with taking the medication it’s good and I am taking it and 
feeling good about myself. Nobody knows my secret. When I am 
taking it, people don’t know. I am good looking but they don’t know 
what’s inside. 
 
P1 sees medication as a way of guarding against an association with the sick role, 
something she clearly wishes to avoid. The medication allows P1 to be good 
looking and hence to feel good about herself. Of course her account has an edge. 
While the medication makes her look better and therefore brings her close to 
others, it also creates a gap as she is left alone ‘inside’ with the shameful secret 
of having HIV. 
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A sense of collaborative agency over the medication 
 
Several of the women expressed that they shared with their doctors a sense of 
joint agency over their medication experience. P1 said:  
 
Any medication that does not fit me and I ask them to, they will 
change it.  
 
Her use of the words ‘fit me’ here emphasise the importance of the medications 
suiting P1, rather than her having to fit around them. She is working in 
conjunction with her healthcare team, whom she feels very confident will switch 
the medicines if she asks them to.  Further to this, P10 says: 
 
So I give to him, this is what I want. So we are going to look for 
medication that goes like. If there is none, we have to check again 
(both laugh)! We have to adopt something, sort of thing! So I was 
quite happy we find what I needed. 
 
There is a strong sense of partnership between P10 and doctor, emphasized by 
the repeated use of ‘we’. Together, they are able find the right medication for her. 
Again, there is a strong sense that the medications are having to fit in with P10’s 
life, rather than her having to submit to their unyielding nature. P10 clearly 
knows what she wants here, and this ability to define her needs and, in 
collaboration with the health-care team, retain her agency leads to a more 
positive relationship with the medication.  
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Relatedly, P6 says:  
 
I like to be active. I don’t like to be sick. Likewise I don’t want to be 
poorly or sick so I like taking my medication the way they have 
prescribed.  
 
P6 has faith in the doctors to help her achieve her desired state of vitality. She 
understands that the doctors’ instructions around the tablets, as well as the 
tablets themselves, are important in terms of adherence and effective treatment. 
Hence we can see here how a feeling of collaboration with the doctors allows 
some of the women to gain an enhanced sense of agency and to feel more 
positive about their treatment regimen. 
 
 
DISCUSSION 
 
Negative experiences of antiretroviral medications 
 
Nine of the 10 women talked about negative experiences around taking ART. A 
novel finding of this work is the degree of difficulty reported in taking the 
medicines, with physical features representing a barrier to taking ART. One 
paper (29) and one review (16) mention that the size and taste of tablets can be 
a barrier to adherence, but this is not explored in any great depth.  
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Sankar et al (17) make the point that, “Stigma is a kind of self-awareness of an 
undesired status” (p. 215). The big, bright, unignorable appearance of ART 
tablets alerts some of the women in the current study to their internalised 
stigma every time they face taking them, which becomes a barrier to adherence. 
This feature of the tablets themselves is worthy of further exploration, perhaps 
via a qualitative study asking participants directly about their feelings around 
the physical features of the tablets, since a deeper understanding of the 
reactions elicited by the appearance of the tablets might illuminate possibilities 
for making them easier to swallow.  
 
Our findings also show that for some participants, there was a disconnect 
between their expectations about ART’s effects and their experience of health. 
Participants felt that they were adhering, but their blood results or symptoms 
were not responding in the ways they expected. For P4, this seemed connected 
to a sense of being entirely passive within the treatment; it was something that 
happened to her, rather than something in which she actively engaged – a 
finding reflected in the experiences of Sankar et al.’s group of ‘somewhat 
adherent’ participants (17).  
 
Earlier research suggested that some people of black African heritage living with 
HIV in London felt that ART wouldn’t work for them because it had been tested 
on white people (30). There was also some suspicion amongst those living with 
HIV at around the same time as to whether ART was harmful rather than 
beneficial (see eg. 17, 29). Our findings suggest that this narrative has moved on. 
While there is no longer a suggestion that ART in general is harmful or doesn’t 
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work, some people living with HIV may feel that ART doesn’t work for them 
personally. This sense of disconnect may come from a lack of understanding of 
how ART works and how to adhere to treatment correctly. There is plenty of 
literature to support the notion that, like our participants, many people taking 
ART believe themselves to be adherent when in fact they are not taking their 
tablets in the correct manner (see eg. 16, 28, 31, 32). Indeed, some findings show 
that worse HIV symptoms correlate with lower adherence (33), suggesting that 
those with the most need have the least knowledge. It seems that despite the 
high rate of education offered to people living with HIV about ART, more work is 
needed in this area.  
 
Many of the women in the current study described their ART regimen as a 
feeling of being trapped in a monotonous life sentence. This could lead to 
feelings of depression, and to deliberately ‘forgetting’ in order to escape the 
prison of adherence. Feelings of hopelessness (28) and depression (16) 
connected to adherence to ART have been noted elsewhere in the literature but 
our work points to the extent of the tedium or relentlessness. Previous findings 
have described examples of deliberate forgetting (see eg. 15, 34) of medications. 
However, these instances are usually connected to issues around stigma, such as 
not wanting to be seen taking drugs, rather than a feeling of monotony 
associated with the regimen. In this way, our novel findings are again suggestive 
of themes to consider when modifying interventions to improve adherence. 
 
Participants in this study also found that social context, in the form of work or 
family life, could have a negative impact on their adherence levels; if participants 
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didn’t want to disclose their HIV status to work colleagues or family members, 
then taking ART near them became challenging. This is a finding that is 
consonant with existing literature. Flowers et al. (12) demonstrate how the 
wider social context of being a person of black African heritage living with HIV in 
London can impact on adherence in terms of concerns about deportation, 
separation from loved ones, problems in accessing healthcare and so on. Just as 
it was for P9 in the current study, living in shared housing presented a problem 
for some of the women in another qualitative study (11). The demands of 
childcare have been named as a barrier to adherence in various studies (16, 17, 
35), whilst family commitments are cited elsewhere (32). We can therefore see 
that social context can make adherence challenging. This problem deepens, since 
a lack of disclosure to loved ones has been shown to lead to social isolation and 
depression, which can create further barriers to adherence (13, 15, 16). It would 
therefore seem that disclosure to understanding friends and family should be 
encouraged, so that social context can be utilised as a support, rather than a 
threat.  
 
Temporal improvement in the experience of medications 
 
Several of the women describe an improvement in their relationship with ART 
as time passes. Tablets became normalised, and participants found treatment 
combinations over time which they believed suited them better. Remien et al. 
(29) have described how adherence to ART is a dynamic process that changes 
over time, which clearly reflects the experiences of these participants.  
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Although previous work has suggested that attitudes towards ART change, it is 
unclear how they change over time. One review (16) suggests that confidence in 
the effectiveness of medications can improve as the medication is shown to 
work through good blood test results, feedback from others, and discussions 
with people who are taking the same combinations (16).  
 
Sankar et al. (17) report that higher adherence correlates with worsening 
symptoms, suggesting a possible improvement in adherence over time. Findings 
elsewhere contradict this, suggesting that adherence in fact worsens as time 
goes on (5) and as symptoms increase (33). These mixed findings highlight the 
benefits of idiographic, qualitative research such as in both the current paper 
and other successful IPA studies (see eg. 20), since the story is unlikely to be the 
same for all people attempting to adhere to ART. Gonzalez et al. (33) highlight 
the need for more longitudinal research to explore this dynamic process of 
adherence to ART, a recommendation which the findings in the current paper 
support. 
 
 Spurs to adherence  
 
Various factors were found to facilitate adherence for the women in the current 
study. As has previously been stated, one paper (33) has shown that increased 
HIV symptoms correlate with a lower level of adherence, a finding which seems 
to contradict the suggestions of the women in the current study that previous 
highly symptomatic periods of time make adherence easier. However, perhaps 
what our study shows is how people living with HIV may react to highly 
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symptomatic periods once they have survived them, rather than how adherent 
they are whilst those periods are taking place. The findings of Sankar et al. (17) 
seem more in line with ours, where participants who had developed AIDS were 
more likely to be adherent than those who were less symptomatic.  Several other 
studies (29, 35) have found that a desire for good health is a strong motivator 
for adherence; it seems logical to guess that such a desire might follow a period 
of extreme ill health. Just as P10 utilised her increased knowledge of HIV as a 
motivator, it has also been found elsewhere that greater knowledge results in 
better adherence (17, 31).  
 
Our in-depth, qualitative findings include the novel finding that conceptual 
motivators for adherence, such as using ART to feel closer to normality, or 
retaining a sense of autonomy over the regimen, can help with adherence. This 
demonstrates further the importance of idiographic work in this field, which can 
highlight hard to access motivators for adherence, and stresses the importance 
for healthcare teams of taking each person who struggles with adherence on an 
individual level and listening to what may be pertinent for them.  
 
Participants also talked about relational facilitators to adherence; family, and 
especially children, were great motivators for several of the women. The impact 
of children on adherence crops up frequently within the existing literature. 
However, this is a complex area, as sometimes children can be motivators, and 
as described above, their presence can be a barrier to adherence. This pattern is 
somewhat mirrored in the current findings, in which we can see that social 
relationships can be both motivational and problematic depending on the 
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circumstances. For example, living with others can work as a barrier, whilst 
caring for children can work as a motivator.   
 
One review of the literature (16) agrees that children can be strong motivators 
for adherence, and that they can also help their parents to remember their 
medications, as we saw P2’s daughter doing. Findings elsewhere (11, 29, 31) 
back up this positive picture. Doyal and Anderson have shown that it is not just 
mothers for whom children work as a spur to adherence; their qualitative study 
looking at heterosexual African men living with HIV in London shows that 
fathers are also aided in their adherence efforts by their children (13).  
 
For some of the participants in Sankar et al.’s study, children worked as a barrier 
to adherence (17). These African-American women lived in fear of their HIV 
status being disclosed. In particular, they worried that their status being 
discovered would lead to bullying and stigmatisation for their children. 
Therefore, if the women were in situations whereby being adherent (such as 
collecting medications from a chemist or taking ART in a public place) might put 
their children at risk from associated stigma, they would be non-adherent.  
 
Interestingly, excellent adherers in another study (28) rarely mentioned other 
people as motivators, but instead were motivated from within, citing a desire to 
stay physically healthy as a major reason for taking ART correctly. In contrast, 
those who felt that others, such as children, relied on them to adhere were more 
likely to fall into the sub-optimal adherence group. However, it should be noted 
that the excellent adherers within this study were open about their HIV status 
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and likely to have strong social support, so perhaps there is an important 
difference to be teased out between a feeling of support and a feeling of 
dependence for some people living with HIV.  
 
Finally, our findings suggest that a sense of collaborating with healthcare teams 
over ART leads to a heightened sense of agency and greater adherence to ART—
which is consistent with existing literature (16, 17, 29, 31). Our work highlights 
how a sense of collaborative involvement with the medical team can also 
enhance the patient’s faith in the efficacy of the regimen. We would therefore 
recommend that clinicians try to involve their patients in decisions around ART 
as much as possible in order to encourage a sense of active engagement within 
care.  
 
Reflections and limitations 
 
Although we believe that this paper is an important contribution to the 
literature around adherence for people of black African heritage living with HIV, 
it does have some limitations. Firstly, identifying non-adherent participants was 
challenging. Adherence can be hard to quantify, since patients may find it hard to 
speak openly with doctors - and indeed researchers - about their adherence 
habits, or may not have the same understanding of adherence as clinicians do 
(28, 36). Consequently, we identified those we believed to be non-adherent by 
looking at blood results and reviewing patient notes, but it is conceivable that 
we didn’t find all the non-adherent participants we could have done. Indeed, the 
most non-adherent patients – and therefore the most vulnerable – will be lost to 
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follow up and therefore impossible to recruit via hospitals. This is an ongoing 
challenge for any researchers tackling the issue of non-adherence (37).  
 
In addition, as mentioned earlier, it might have been useful to speak to those 
who did adhere well to their medication in order to uncover information about 
facilitators for adherence. However, this would have compromised IPA’s 
principle of homogeneity (19), so wouldn’t have been appropriate for this study. 
Future researchers may wish to speak to this patient group.  
 
We explained earlier in the paper our rationale for a homogeneous sample of 
black West African women. This enabled us to examine the personal experience 
this specific group in some depth. It would be valuable to follow this study up 
with further work with other purposively selected samples, for example black 
West African men, sub-Saharan women, sub-Saharan men. 
 
We consider this paper to offer a detailed insight into patients’ experience of HIV 
medication, and believe it is the use of IPA that has enabled this. Of course, any 
single study and any one methodology can only offer a partial contribution to 
the bigger picture. The growing receptivity to a wider repertoire of 
methodologies within the social and health sciences means that we will 
increasingly be able to explore topics through a range of different lenses, and the 
triangulation of those different perspectives will afford a more comprehensive 
and complete portrait of the phenomenon under investigation. 
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CONCLUSION 
 
In this paper we have presented in-depth, idiographic findings from an 
interpretative phenomenological analysis of the experience of medication in a 
purposively selected group of West African women of black heritage living with 
HIV in London, UK. We have provided detailed evidence of their negative 
experience of adhering to the aversive regimen of the medication, which could 
leave the women feeling trapped. Our findings have also demonstrated how for 
some, treatment had improved over time. Further, we have pointed to factors 
which can act as spurs to adherence. We consider the paper to make a 
contribution in its own terms but we hope it may also act as a catalyst to further 
detailed research on the experience of other groups of people living with HIV, or 
other people having difficulties adhering to potential stigmatising medication 
regimes. 
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Table i: Demographic information for the participants 
 
 
Name Age Marital 
Status 
No. of 
child- 
ren 
Country of 
origin 
Years 
in UK 
Job status Date of 
diagnosis 
P1 42 Separated 3 Sierra Leone 7 Unemployed 2006 
P2 43 Single 1 Nigeria 16 Student 2001 
P3 56 Single 0 Ghana 56 Unemployed 1999 
P4 32 Cohabiting 2 Nigeria 10 Employed 2003 
P5 44 Widow 2 Nigeria 13 Employed 2002 
P6 46 Married 6 Nigeria 6 Unemployed 2005 
P7 42 Single 2 Nigeria 14 Employed 2003 
P8 42 Divorced 3 Ivory Coast 10 Employed 1996 
P9 40 Single 1 Nigeria 8 Employed 2003 
P10 30 Cohabiting 0 Guinea 6 Employed 2008 
 
  
 47 
Table ii: Table of themes 
 
Master themes:  Negative 
experience of 
medications 
Temporal 
improvement in 
the experience of 
medication 
Spurs to 
adherence 
Sub-themes:  An aversive 
regimen 
 
 Intrinsic motivators 
 Disconnect between 
treatment and 
feeling of health 
 Relational 
motivators 
 Feeling trapped in a 
monotonous life 
sentence 
 Sense of 
collaborative 
agency over the 
medication  
 Social context 
exacerbates the 
difficulties  
  
 
 
 
 
